ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Economics"

  • Abstract Number: 199 • 2017 ACR/ARHP Annual Meeting

    Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study

    Natalie McCormick1,2, Carlo Marra3 and J. Antonio Avina-Zubieta4, 1Arthritis Research Canada, Richmond, BC, Canada, 2Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, 3School of Pharmacy, University of Otago, Dunedin, New Zealand, 4Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Little is known about the healthcare costs of systemic lupus erythematosus (SLE) patients in the years leading up to SLE diagnosis.  We estimated the…
  • Abstract Number: 224 • 2017 ACR/ARHP Annual Meeting

    Patterns of Methotrexate Use in African Countries with Low Versus Medium/High Human Development Index: Preliminary Results of Semi-Structured Interviews

    Carol A Hitchon1, Yan Liu2, Steven Shi3, Girish M Mody4, Candace H. Feldman5, Michael Weinblatt6 and Ines Colmegna7, 1Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 2McGill University, Montreal, QC, Canada, 3University de Montreal, Montreal, QC, Canada, 4Dept of Rheumatology, University of Kwa Zulu-Natal, Durban, South Africa, 5Brigham and Women’s Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA, 6Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Division of Rheumatology, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada

    Background/Purpose: Methotrexate (MTX) is standard therapy for rheumatoid arthritis (RA) and also used to treat other rheumatic diseases. Existing guidelines for RA treatment/ MTX use…
  • Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting

    Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission

    Melanie Hagen1, Matthias Englbrecht2, Judith Haschka3, Michaela Reiser4, Arnd Kleyer5, Axel J. Hueber6, Bernhard Manger7, Camille Figueiredo8, Jayme Fogagnolo Cobra9, Hans-Peter Tony10, Stefanie Finzel11, Stefan Kleinert12, Joerg Wendler13, Florian Schuch13, Monika Ronneberger13, Martin Feuchtenberger14, Martin Fleck15,16, Karin Manger17, Matthias Schmitt-Haendle18, H.-M. Lorenz19, HG Nüßlein20, Rieke Alten21, Joerg C. Henes22, Klaus Krüger23, Georg Schett2 and Juergen Rech24, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 3Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, 4Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5Dept of Medicine 3, Rheumatology and Clinical Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, 6Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 7Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 8Institution de Rheumatologia, Sao Paolo, Brazil, 9Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, 10Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, 11University of Freiburg, Freiburg, Germany, 12Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, 13Schwerpunktpraxis Rheumatologie, Erlangen, Germany, 14Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 15Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, 16Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, 17Rheumatology Practice Bamberg, Bamberg, Germany, 18Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, 19Rheumatology, University Heidelberg, Heidelberg, Germany, 20Rheumatology Practice Nuremberg, Nuremberg, Germany, 21Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 22Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, 23Praxiszentrum St.Bonifatius, Munich, Germany, 24Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany

    Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
  • Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting

    Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor

    Aliza Matusevich1, Maria Suarez-Almazor1, Scott B. Cantor2 and Maria A. Lopez-Olivo1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…
  • Abstract Number: 1059 • 2017 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Tai Chi Versus Physical Therapy for Knee Osteoarthritis

    John B. Wong1, Mei Chung2, Lori Lyn Price3 and Chenchen Wang4,5, 1Tufts Medical Center, Boston, MA, 2Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, 3Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, 4Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, 5Division of Rheumatology, Tufts Medical Center, Boston, MA

    Background/Purpose: A single-blind randomized comparative effectiveness trial showed that Tai Chi yielded beneficial effects similar to those of a standard course of physical therapy in…
  • Abstract Number: 1080 • 2017 ACR/ARHP Annual Meeting

    Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction

    Y. Ingrid Goh1, Talia Goldberg2, Nicholas Lao3 and Brian M. Feldman4, 1Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Western Ontario, London, ON, Canada, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver SatisfactionBackground/Purpose: Patient reported outcomes (PROs) are powerful tools that facilitate…
  • Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting

    Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study

    Annalisa Montante1, Alicia Le Bras2, Benjamin Terrier3, Pascal Cohen3, Xavier Puéchal4, Alexandre Karras5, Philippe Ravaud6, Loïc Guillevin7 and Isabelle Durand-Zaleski8, 1UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, 2UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, 3Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 4Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, 5Nephrology, HEGP, Paris, France, 6Hôpital Hôtel Dieu, Paris, France, 7Internal medicine, Cochin University Hospital, paris, France, 8UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France

    Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
  • Abstract Number: 113 • 2016 ACR/ARHP Annual Meeting

    Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tools: A Study of Medical Economics

    Fei Xiao1, Xiangyuan Liu2, Zhijun Li3, Tong Xie4, Xinwang Duan5, Huiqiong Zhou6, Yanhong Huang7, Yi Zheng8, Hua Wei9, Hongzhi Wang10, Rong Mu11, Hui Xiao1, Yuhua Jia1, Yonggang Zhao1, Yuan Liu1 and Fengchun Zhang12, 1Gothic Internet Technology Corporation, Shanghai, China, 2Department of Rheumatology and Immunology, Peking University Third hospital, Bei jing, China, 3The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 4Affiliated hospital of Guangdong medical University, Zhanjiang, China, 5Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, 6The First Affiliated Hospital of PLA General Hospital, Beijing, China, 7Beijing Jishuitan Hospital, Beijing, China, 88 Gongren Tiyuchang Nanlu, Cha, Beijing Chao-Yang Hospital, Beijing, China, 9No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, 10The First Hospital of Jiaxing, Jiaxing, China, 11Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 12Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Background/Purpose: China does not have primary medical care and referral system. Patients can choose any hospital or any doctor they like to seek medical care.…
  • Abstract Number: 228 • 2016 ACR/ARHP Annual Meeting

    Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study  

    Valgerdur R Sigurdardottir1, Lennart TH Jacobsson2, Panagiota Drivelegka2, Anna Svärd1,3 and Mats Dehlin2, 1Rheumatology Clinic, Falun Hospital, SE-791 82 Falun, Sweden, Falun, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Center for Clinical Research Dalarna, Falun, Sweden

    Background/Purpose: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50-59 years. Gout…
  • Abstract Number: 1237 • 2016 ACR/ARHP Annual Meeting

    The Economic Burden of Dermatomyositis and Polymyositis in the US

    J. Bradford Rice1, Alan White1, Philip Galebach1, Andrea Lopez1, Patricia Schepman2, Breanna Popelar3, Michael Philbin4 and Elaine Boing2, 1Analysis Group, Inc., Boston, MA, 2Affiliated with Mallinckrodt Pharmaceuticals at the time this study was conducted, Hazelwood, MO, 3Xcenda, L.L.C., Palm Harbor, FL, 4Mallinckrodt Pharmaceuticals, Hazelwood, MO

    Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies that can lead to persistent muscle weakness and disability. Although significant healthcare resource utilization (HCRU) and work…
  • Abstract Number: 1243 • 2016 ACR/ARHP Annual Meeting

    Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis

    Cécile Gaujoux-Viala1, Laure Gossec2, Christel Castelli3, Cédric Lukas4, Françoise Barchechath-Flaisler5, Jean-Pierre Daures6 and Maxime Dougados7, 1Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, 2Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 3BESPIM, Nîmes University Hospital and EA2415, Nîmes, France, 4Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 5Nîmes University Hospital, Rheumatology Department, Nimes, France, 6EA2415, Nîmes, France, 7Paris Descartes University, Paris, France

    Background/Purpose:  The quantification of health improvements is essential, notably in the current context of increasingly expensive therapies and more and more limited resources. Preference-based measures…
  • Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting

    The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients

    Alan Glicklich1, Paul Grayson1, Christophe Blanchetot2, Qing Zhou3 and Anke Kretz-Rommel1, 1Bird Rock Bio, Inc, La Jolla, CA, 2Argenx, Ghent, Belgium, 3Genor BioPharma, Shanghai, China

    Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
  • Abstract Number: 2252 • 2016 ACR/ARHP Annual Meeting

    Estimated Cost of SLE Hospitalizations

    Kayla Neville1, James Miceli1, Jianhua Li2, Samantha Nguyen3, Teja Kapoor3 and Anca Askanase3, 1Rheumatology, Columbia University Medical Center, New York, NY, 2Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, 3Medicine, Division of Rheumatology, Columbia University Medical Center, New York, NY

    Background/Purpose:  Systemic lupus erythematosus (SLE) treatment comes at a high price, with both direct costs related to healthcare resource utilization and indirect ones related to…
  • Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting

    Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)

    JoAnne Foody1, Robin Turpin2, Beni Tidwell3 and Kathy Schulman4, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, 3ORS, Shrewsbury, MA, 4Outcomes Research Solutions, Inc., Waltham, MA

    Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
  • Abstract Number: 2473 • 2015 ACR/ARHP Annual Meeting

    Psycho-Socio-Economic Burdens of Childhood Onset Rheumatic Diseases on Families

    Sook Fun Hoh1, Manasita Tanya2, Justin Hung Tiong Tan2, Lena Das2,3 and Thaschawee Arkachaisri2, 1Nursing, KK Women's and Children's Hospital, Singapore, Singapore, 2Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 3Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH

     Background/Purpose: Rheumatic diseases (RD) in children, being complex and chronic in nature, do not only pose physical insult to the affected child, but also psychological…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology